Why Alembic Pharma shares are in focus today? Check details here

Shares of the Vadodara-based drug maker will be in focus on Monday after the company informed exchanges that the US Food and Drug Administration (USFDA) conducted inspection at its Bioequivalence Facility in Vadodara and issued Form 483 with one inspection which was procedural in nature.

Form 483 issued by the USFDA to a company to alert a company about potentially problematic areas that require attention.

Alembic Pharmaceuticals in a notification said that USFDA conducted a scheduled inspection at its Bioequivalence Facility located at Vadodara from March 3-7, 2025 and issued Form 483 with one observation.

"The Company will provide comprehensive response to USFDA for the observations within the stipulated period. The Company is committed to maintain the highest quality standards and compliance at all times," Alembic Pharma said in a stock exchange filing.

Alembic Pharma shares closed 0.04% higher at ₹845 on the NSE on Friday. The stock has so far this year tumbled 21% underperforming the Nifty Pharma index which has declined 13%.

Meanwhile, Sun Pharma, Lupin and Shilpa Medicare from the pharma space will also be in focus today.